TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8256188

Group type: EXPERIMENTAL
Intervention: Cefepime (2 grams every 12 hours)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Gentamicin and mezlocillin (gentamicin 1.0 to 1.5 mg/kg every 8 hours; mezlocillin 3 to 4 grams every 4 to 6 hours)
Number of subjects: 149
Study: 3321867

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31370128

Group type: EXPERIMENTAL
Intervention: 10 mg oral prednisolone twice daily for four days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 28882536

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2 on day 1 every 3 weeks
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Gemcitabine 675 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8 every 3 weeks
Number of subjects: 257
Study: 25603432

Group type: EXPERIMENTAL
Intervention: Glucose-drink and rest
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose-drink and exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water and exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose-drink
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water and rest
Number of subjects: 30
Study: 23991092

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (Lap-Hx)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Open liver resection (Open-Hx)
Number of subjects: 275
Study: 21194670

Group type: EXPERIMENTAL
Intervention: Integrative health coaching (2 to 28 sessions)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Integrative health coaching
Number of subjects: 360
Study: 19487177

Group type: EXPERIMENTAL
Intervention: Fosamprenavir-ritonavir (FPV/r) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Lopinavir-ritonavir (LPV/r) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Fosamprenavir-ritonavir (FPV/r)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Lopinavir-ritonavir (LPV/r)
Number of subjects: 199
Study: 17673814

Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m2, every 3 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2, every 3 weeks) + 5'DFUR (600 mg/body)
Number of subjects: 24
Study: 15152060

Group type: EXPERIMENTAL
Intervention: Standard medical therapy plus a single-chamber ICD
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study: 11332171

Group type: EXPERIMENTAL
Intervention: Beractant (100 mg kg-1) administered 2 hours after the first dose
Number of subjects: 57

Group type: COMPARATOR
Intervention: Beractant (100 mg kg-1) administered 6 hours after the first dose
Number of subjects: 57
Study: 9433436

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7995165

Group type: EXPERIMENTAL
Intervention: Defecography assessment by three observers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Defecography assessment with clinical data provided
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Defecography assessment with residual volume in the lower rectum
Number of subjects: 100
Study: 3143539

Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg three times daily up to 0.25 mg twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral digoxin (0.125 mg twice daily) and quinidine hydrogen sulphate (750‐1000 mg daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral digoxin (0.125 mg three times daily) and flecainide (200‐300 mg daily)
Number of subjects: 45
Study: 31244349

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 112
Study: 28442337

Group type: EXPERIMENTAL
Intervention: Three-Factor Eating Questionnaire (TFEQ)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Weight-Related Eating Questionnaire (WREQ)
Number of subjects: 186
Study: 26488118

Group type: EXPERIMENTAL
Intervention: LE‐HMF
Number of subjects: 147

Group type: COMPARATOR
Intervention: PI‐HMF
Number of subjects: 147
Study: 23885033

Group type: EXPERIMENTAL
Intervention: MenACWY-TT lot A (ACWY-A) (68% O-acetylation)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: MenACWY-TT lot B (ACWY-B) (92% O-acetylation)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Men-PS (82% O-acetylation)
Number of subjects: 1170
Study: 21806572

Group type: EXPERIMENTAL
Intervention: Predictive model based on clinical characteristics and laboratory findings
Number of subjects: 703
Study: 19531265

Group type: EXPERIMENTAL
Intervention: Tele-based psychologist delivered five session individualised cognitive behavioural intervention
Number of subjects: 560

Group type: COMPARATOR
Intervention: Minimal contact self management
Number of subjects: 560
Study: 16684279

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aseponate (MPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Normal skin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcipotriol and MPA
Number of subjects: 30
Study: 16279272

Group type: EXPERIMENTAL
Intervention: Most intensive, church‐based intervention arm
Number of subjects: 12400

Group type: EXPERIMENTAL
Intervention: Other two intervention arms
Number of subjects: 12400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12400
Study: 11368136

Group type: EXPERIMENTAL
Intervention: Perineal massage
Number of subjects: 684
Study: 9224961

Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (400 mg every 8 hours for 30 days) + Rifabutin (300 mg once daily on days 16-30)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delavirdine mesylate (400 mg every 8 hours for 30 days)
Number of subjects: 12
Study: 7737957

Group type: EXPERIMENTAL
Intervention: Fluoxetine (antidepressant) for 12 weeks
Number of subjects: 200
Study: 2183734

Group type: EXPERIMENTAL
Intervention: Forced diuresis, chemotherapy, and plasmapheresis (group 2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Forced diuresis and chemotherapy (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 21
Study: 457316

Group type: EXPERIMENTAL
Intervention: Topical salicylic acid in hydrophilic ointment applied to skin with removed stratum corneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical salicylic acid in hydrophilic ointment applied to intact skin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical salicylic acid in polyethylene glycol 400 vehicle
Number of subjects: 0
Study: 31174172

Group type: EXPERIMENTAL
Intervention: Society of Critical Care Prioritization Model
Number of subjects: 257

Group type: COMPARATOR
Intervention: Cancer specific flowchart
Number of subjects: 257
Study: 28591240

Group type: EXPERIMENTAL
Intervention: Sealant treatment (n = 28)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Restorative treatment (n = 26)
Number of subjects: 49
Study: 25887235

Group type: EXPERIMENTAL
Intervention: MultiComponent Exercise and theRApeutic lifeStyle (CERgAS) intervention program
Number of subjects: 164

Group type: COMPARATOR
Intervention: General health education (Control)
Number of subjects: 164
Study: 24843061

Group type: EXPERIMENTAL
Intervention: Follow-up formula (FUF) with 25 mg DHA, 1.2 g PDX/GOS, and 8.7 mg yeast β‐glucan per serving, 3 servings per day for 28 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up formula (FUF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (unfortified, cow's milk‐based beverage)
Number of subjects: 100
Study: 22773430

Group type: EXPERIMENTAL
Intervention: Acebron™ 4 mg (Test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neo‐Sintrom™ 4 mg (Reference)
Number of subjects: 24
Study: 20142065

Group type: EXPERIMENTAL
Intervention: Hip Protector (HP) worn on the right or left side
Number of subjects: 797
Study: 18052556

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 21
Study: 16269090

Group type: EXPERIMENTAL
Intervention: hBD-4 peptides from LPS-treated small airway epithelial cells (SAECs)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hBD-4 peptides in patients with chronic LRTI
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (untreated SAECs)
Number of subjects: 6
Study: 12122176

Group type: EXPERIMENTAL
Intervention: FULL (six days of bed rest)
Number of subjects: 107

Group type: COMPARATOR
Intervention: NO (no bed rest)
Number of subjects: 107
Study: 10098562

Group type: EXPERIMENTAL
Intervention: Mixed-mode method
Number of subjects: 930

Group type: COMPARATOR
Intervention: Telephone-mode sample
Number of subjects: 930

Group type: COMPARATOR
Intervention: Second telephone-mode sample with enhanced locating procedures
Number of subjects: 930
Study: 8683518

Group type: EXPERIMENTAL
Intervention: Percentage weight loss (%WL)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mid-arm muscle circumference (MAMC)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of %WL, BMI, and MAMC
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fluid retention
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All three measurements (%WL, BMI, MAMC)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Assessment by dietitian
Number of subjects: 84
Study: 1522190

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG) 1500 IU i.m. on days 3, 6, and 9 after the initial trigger
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intramuscular progesterone 12.5 mg q.d. starting from the day after the HCG trigger, increased to 25 mg q.d. on the day of embryo transfer
Number of subjects: 121
Study: 6347232

Group type: EXPERIMENTAL
Intervention: Aspirin (0.3-1.2 g single dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Other nonsteroidal anti-inflammatory drugs (oral challenge)
Number of subjects: 6
Study: 31274814

Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Current CMS penalties
Number of subjects: 3000
Study: 27807213

Group type: COMPARATOR
Intervention: Glucocorticoid therapy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy
Number of subjects: 119
Study: 25867415

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine A (CsA) alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Combination of low-dose hormone and low-dose CsA
Number of subjects: 27
Study: 23965841

Group type: EXPERIMENTAL
Intervention: Energy deficit (ED)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mixed-meal consumption
Number of subjects: 39

Group type: COMPARATOR
Intervention: Weight maintenance (WM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 39
Study: 21420129

Group type: EXPERIMENTAL
Intervention: Intensive glycemic therapy
Number of subjects: 761

Group type: COMPARATOR
Intervention: Conventional glycemic therapy
Number of subjects: 761
Study: 20214212

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy with pelvic autonomic nerve preservation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group without radiation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Number of subjects: 24
Study: 17146364

Group type: EXPERIMENTAL
Intervention: Drains (20 patients, 20 hips)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drains (20 patients, 20 hips)
Number of subjects: 40
Study: 14966097

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg i.v. before chemotherapy plus 4 mg orally every 6 hours for four doses (arm A)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg i.v. single dose before chemotherapy (arm B)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg i.v. single dose before chemotherapy (arm C)
Number of subjects: 587
Study: 11337977

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.9 g daily for 63 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 17
Study: 1544953

Group type: EXPERIMENTAL
Intervention: Sheffield splint (cast immobilisation for three weeks followed by controlled early mobilisation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sheffield splint
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plaster cast (cast immobilisation for eight weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 40
Study: 3922535

Group type: EXPERIMENTAL
Intervention: Leucotriene D4
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 17
Study: 29544472

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) - 2 g 2 hours before incision, 1 g at 6 and 12 hours after surgery
Number of subjects: 147

Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid (TXA) - 3 g in 100 mL of saline solution
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid (TXA)
Number of subjects: 147
Study: 27265814

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Delayed palliative care (EPC) intervention
Number of subjects: 123
Study: 24793963

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus GG and Bifidobacterium animalis ssp. lactis BB‐12)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (placebo tablet)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 192
Study: 22628382

Group type: EXPERIMENTAL
Intervention: Participants with greater domestic violence myths
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Victim who returned to her abuser
Number of subjects: 194
Study: 20113305

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Treatment as usual plus waiting list for DBT (TAU+WL)
Number of subjects: 73
Study: 17888516

Group type: EXPERIMENTAL
Intervention: Open-phase divalproex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-phase lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study: 15841383

Group type: EXPERIMENTAL
Intervention: Bone bruise with intra-articular pathology
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Bone bruise without intra-articular pathology
Number of subjects: 664

Group type: COMPARATOR
Intervention: No bone bruise with intra-articular pathology
Number of subjects: 664

Group type: COMPARATOR
Intervention: No bone bruise without intra-articular pathology
Number of subjects: 664
Study: 12847484

Group type: EXPERIMENTAL
Intervention: Exposure to kitchen Bla g 1 levels greater than 1 U/g
Number of subjects: 339
Study: 11016468

Group type: EXPERIMENTAL
Intervention: HAI plus systemic fluorouracil/folinic acid
Number of subjects: 84

Group type: COMPARATOR
Intervention: Systemic fluorouracil/folinic acid
Number of subjects: 84
Study: 9001834

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg administered at bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1516762

Group type: EXPERIMENTAL
Intervention: Intensified diet education and continuous encouragement to increase physical activity
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventionally treated group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 78
Study: 2870754

Group type: EXPERIMENTAL
Intervention: Active trial or standard medication
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 31487415

Group type: EXPERIMENTAL
Intervention: Best Possible Self (BPS) intervention
Number of subjects: 0
Study: 29637824

Group type: EXPERIMENTAL
Intervention: Externally applied electroceutical (EAE) device, Accel-Heal, applied for 12 consecutive days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo device, identical in appearance to the EAE device, applied for 12 consecutive days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EAE device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 0
Study: 26856220

Group type: EXPERIMENTAL
Intervention: Aggressive hydration with normal saline guided by left ventricular end-diastolic pressure (LVEDP)
Number of subjects: 560

Group type: COMPARATOR
Intervention: General hydration (control group) with <500 mL normal saline at a normal rate (0.5 or 1 mL/kg.h)
Number of subjects: 560
Study: 24795094

Group type: EXPERIMENTAL
Intervention: RHANI Wives intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 22873210

Group type: EXPERIMENTAL
Intervention: Interactive neurostimulation (INS) therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23
Study: 22197956

Group type: EXPERIMENTAL
Intervention: Low-frequency force steadiness practice in plantar flexor muscles (5 sets of 60-s contraction at 10% and 20% MVC, once or twice a week for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-exercising control group (n=7)
Number of subjects: 21
Study: 19231198

Group type: EXPERIMENTAL
Intervention: N‐butyl octyl cyanoacrylate (NCA) tissue adhesive
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional methods (nylon monofilament, traditional skin sutures, or metal skin clips)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Skin clips subgroup
Number of subjects: 40
Study: 16809568

Group type: EXPERIMENTAL
Intervention: ADMA (0.10 mg ADMA/kg per min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study: 12780424

Group type: EXPERIMENTAL
Intervention: Advice plus iron supplement (60 mg Fe2+ - Ferromax)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+ - Hemofer)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Advice only (Group I)
Number of subjects: 326
Study: 11124651

Group type: EXPERIMENTAL
Intervention: 12.5 microg fenoterol via RMT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 25 microg fenoterol via RMT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 50 microg fenoterol via RMT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 100 microg fenoterol via RMT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 200 microg fenoterol via RMT
Number of subjects: 62

Group type: COMPARATOR
Intervention: 100 microg fenoterol via MDI
Number of subjects: 62

Group type: COMPARATOR
Intervention: 200 microg fenoterol via MDI
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9360504

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (2.5 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (5 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (10 mg)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (15 mg)
Number of subjects: 137
Study: 1548889

Group type: EXPERIMENTAL
Intervention: Hickman catheters
Number of subjects: 141

Group type: COMPARATOR
Intervention: Implanted port catheters
Number of subjects: 141
Study: 3900846

Group type: EXPERIMENTAL
Intervention: Vitamin E (5 mg/dL)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study: 31720905

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism-based analysis (SBA) method using low-coverage whole-genome sequencing (LC-WGS)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Mass spectrometry verification of negative samples
Number of subjects: 213
Study: 30025152

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 minutes) with real ABM
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham tDCS (30 seconds) with control ABM
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Active tDCS with control ABM
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham tDCS with real ABM
Number of subjects: 98
Study: 27177838

Group type: EXPERIMENTAL
Intervention: Central Sleep Apnea (CSA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Obstructive Sleep Apnea (OSA)
Number of subjects: 132
Study: 24694337

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (0.1 mg/d via continuous delivery skin patch)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Progesterone (100 mg/d via vaginal insert)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Testosterone (12.5 mg/d via skin gel)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 22319034

Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-calorie diet and sedentary lifestyle with prednisolone (37.5 mg once daily)
Number of subjects: 10
Study: 20926001

Group type: EXPERIMENTAL
Intervention: Topical ionized solution (IS)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Topical saline solution (placebo)
Number of subjects: 529
Study: 18618034

Group type: EXPERIMENTAL
Intervention: 17% carbamide peroxide gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0% carbamide peroxide gel (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All test groups (17% and 10% carbamide peroxide)
Number of subjects: 30
Study: 16418559

Group type: EXPERIMENTAL
Intervention: Abdominal meridian massage for 5 minutes per day during 6 days from the fifth day before menstruation to the first day of menstruation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 85